AAGQ BIOLOGICAL TECHNOLOGY CO., LIMITED – Trademark Portfolio

Entity Type: 99

AAGQ BIOLOGICAL TECHNOLOGY CO., LIMITED holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include AAGQ. The owner is based in KOWLOON.

ROOM 02 ,21/F, HIP KWAN COMMERCIAL

BUILDING, 38 PITT STREET, YAU MA TEI

KOWLOON 999077 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

AAGQ
AAGQ
Registered 2022
AAGQ
AAGQ
Registered 2020

Trademark Classifications

AAGQ BIOLOGICAL TECHNOLOGY CO., LIMITED's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does AAGQ BIOLOGICAL TECHNOLOGY CO., LIMITED have?

AAGQ BIOLOGICAL TECHNOLOGY CO., LIMITED has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does AAGQ BIOLOGICAL TECHNOLOGY CO., LIMITED file in?

AAGQ BIOLOGICAL TECHNOLOGY CO., LIMITED files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are AAGQ BIOLOGICAL TECHNOLOGY CO., LIMITED's most well-known trademarks?

AAGQ BIOLOGICAL TECHNOLOGY CO., LIMITED's registered trademark portfolio includes well-known marks such as AAGQ. These are among 2 currently registered trademarks in the portfolio.

What is AAGQ BIOLOGICAL TECHNOLOGY CO., LIMITED's trademark registration success rate?

AAGQ BIOLOGICAL TECHNOLOGY CO., LIMITED has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.